Loading data for ALMR — first visit, this takes a few seconds.

알림

Alamar Biosciences Inc. (ALMR)

NasdaqGS: ALMR · 실시간 가격 · USD

34.94

+0.30 (0.87%)

종가 기준: Aug 20, 2026, 3:59 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

0.87% (1D)

매수호가	24.84
시가총액	2.42B
매출 (ttm)	100.42M
순이익 (ttm)	-49.66M
	n/a
	-0.72
	n/a
	-64.41
P/B (ttm)	7.75
P/S (ttm)	24.14
실적 발표일	Nov 5, 2026

매도호가	43.98
거래량	5,704
평균 거래량 (20일)	321,498
시가	34.93
전일 종가	34.64
일중 범위	34.93 - 35.45
52주 범위	18.85 - 38.54
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

ALMR 소개

Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomar...

[더 보기]

산업 Medical Devices

섹터 Healthcare

IPO 일자 Apr 17, 2026

직원 수 286

상장 거래소 NasdaqGS

티커 ALMR

웹사이트 https://alamarbio.com

전체 기업 정보

재무 실적

2025년 Alamar Biosciences의 매출은 74.21M로, 전년 25.14M 대비 195.17% 증가했습니다. 순이익은 -29.82M로, -36.65% 감소했습니다.

재무제표

어닝 서프라이즈

Alamar Biosciences가 Aug 10, 2026에 분기 실적을 발표했습니다:

매출 $26.04M 예상치 하회 $0, 및 Infinity% 전년 대비 성장.

EPS -0.2 예상치 상회 0.12, 및 -Infinity% 전년 대비 감소.

다음 실적 발표

Alamar Biosciences Inc.의 실적 발표 예정일은 Nov 5, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1주 전 · GuruFocus.com

Alamar Biosciences Inc (ALMR) (Q2 2026) Earnings Call Highlights: Revenue Surges 82% on 147% ...

Record 60% gross margin and expanded ADDI partnership position the company for 59% annual growth, despite widening net losses and near-term margin fluctuations.

1주 전 · Simply Wall St.

Alamar Biosciences (ALMR) Stock Trades At A Premium To Its Sales

Alamar Biosciences stock has gained 27.2% year to date, yet the company currently screens as expensive on Simply Wall St's broader valuation checks. That mix of strong recent returns and a low value s...

1주 전 · MarketBeat

Alamar Biosciences Q2 Earnings Call Highlights

Alamar Biosciences (NASDAQ:ALMR) reported second-quarter 2026 revenue of $29.4 million, up 82% from $16.2 million a year earlier, as growth in consumables, instrument placements and service revenue su...

2주 전 · BioPharma Dive

Attovia adds to biotech IPO momentum with $289M offering

The startup is the 12th drug company to bank at least $250 million in an IPO this year, nearly matching totals last seen during the sector’s pandemic peak, according to BioPharma Dive data.

1개월 전 · BioPharma Dive

Braveheart, Attovia join next wave of biotech IPOs

The heart drug developer and immune disease specialist aim to capitalize on momentum that’s already yielded several big-ticket IPOs this year.

2 페이지 중 1

Alamar Biosciences Inc. (ALMR)